NCT06015659View on ClinicalTrials.gov

ZN-c3 + Gemcitabine in Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions
Advanced Pancreatic AdenocarcinomaPancreatic CancerPancreatic Ductal Adenocarcinoma
Interventions
DRUG

Zentalis

Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.

DRUG

Gemzar

Nucleoside metabolic inhibitor, per standard care via intravenous infusion.

Trial Locations (1)

02215

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Lustgarten Foundation

OTHER

collaborator

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

INDUSTRY

collaborator

Stand Up To Cancer

OTHER

lead

Brandon Huffman, MD

OTHER

NCT06015659 - ZN-c3 + Gemcitabine in Pancreatic Cancer | Biotech Hunter | Biotech Hunter